CoChat

Cancer risk in heterozygotes for ataxia-telangiectasia

Open access
Geoffroy-Perez, B�atrice, Janin, Nicolas, Ossian, Katia, Laug�, Anthony, Croquette, Marie-Fran�oise, Griscelli, Claude, Debr�, Marianne, Bressac-de-Paillerets, Brigitte, Aurias, Alain, Stoppa-Lyonnet, Dominique, Andrieu, Nadine · 2001 · International Journal of Cancer
Cited by 134

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Epidemiological studies have suggested that ataxia-telangiectasia (AT) heterozygotes have a predisposition to cancer, especially breast cancer in women. Now, haplotyping can identify heterozygotes for AT mutation (ATM) in AT families, allowing the risk of cancer associated with ATM heterozygosity status to be better assessed. We report a family study of AT patients, in which we estimated the risk of cancer according to ATM heterozygosity status. We analyzed demographic characteristics and occurrence of cancer in 1,423 relatives of AT patients. Haplotyping was performed in living relatives. The probability of being heterozygotes for ATM was calculated for deceased relatives. The risk of developing cancer was estimated in the cohort of relatives, and expected numbers of cancer cases were calculated from French age period-specific incidence rates. The number of cancers at all sites in the total population of relatives was not higher than expected. However, significant heterogeneity was found according to ATM heterozygosity status. This is mainly due to the increased risk of breast cancer previously observed in obligate heterozygotes. In obligate heterozygotes, relative risk (RR) was non-significantly increased for thyroid cancer, leukemia and liver cancer. Risks of ovarian, lung, pancreatic, kidney, stomach and colorectal cancers were non-significantly increased in the group with 0.5 probability of being heterozygotes. The RR was not significantly increased for any site of cancer, except for breast. Therefore, there is no evidence that specific screening of relatives of AT patients would be justified at particular sites other than the breast. However, the amplitude of the risk of breast cancer estimated in heterozygous women does not appear to justify a separate screening program from that already available to women with a first-degree relative affected by breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.1329

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 134

Metadata

Authors
Geoffroy-Perez, B., Janin, N., Ossian, K., Laug�, A., Croquette, M.-F., Griscelli, C., Debr�, M., Bressac-de-Paillerets, B., Aurias, A., Stoppa-Lyonnet, D., & Andrieu, N.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2001
Volume
93
Issue
2
Pages
288-293
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W1991930102
Cited by
134
References
3
FWCI
3.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer risk in heterozygotes for ataxia-telangiectasia. https://app.cochat.ai/papers/10.1002/ijc.1329
The paper
Geoffroy-Perez, B., Janin, N., Ossian, K., Laug�, A., Croquette, M.-F., Griscelli, C., Debr�, M., Bressac-de-Paillerets, B., Aurias, A., Stoppa-Lyonnet, D., & Andrieu, N. (2001). Cancer risk in heterozygotes for ataxia-telangiectasia. International Journal of Cancer. https://doi.org/10.1002/ijc.1329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.